A Kaplan-Meier survival analysis of the TCGA prostate adenocarcinoma dataset using the UCSC Xena platform indicated a trend of survival disadvantage for patients with high E2F1 expression (top 25%) in comparison to those with low E2F1 expression (bottom 25%) (Figure S2E). This evidence concerns the gene E2F1 and prostate adenocarcinoma.